Until now, it was known that, despite their benefits for preventing cardiovascular diseases, antiplatelet drugs could be damaging to the digestive system. The Catalan Institute of Pharmacology Foundation (FICF) has recently shown its incidence in patients who have a risk of upper grastrointestinal bleeding (UGIB).